Workflow
Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.
Sol-GelSol-Gel(US:SLGL) Globenewswire·2025-04-17 20:40

Sol-Gel to receive 16millionduring2025Cashrunwayisexpectedtoextendintothefirstquarterof2027;CompanyexpectstohavesufficientcashtocompleteitsPhaseIIIclinicaltrialSGT−610PhaseIIIclinicaltrialtop−lineresultsareexpectedinthefourthquarterof2026;asignificantmilestoneintheclinicaltrialofrecruitingmorethan8016 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between 400 to $500 million annuallySGT-210 Phase 1b tri ...